Search
for

    Sort by

    Research 571–600 of 1000+

    1. Low-dose finasteride in benign prostatic hyperplasia: a comprehensive narrative review of efficacy, safety, and preventative potential Translational Andrology and Urology · 2026
    2. Moving Chemoprevention Forward into the Most Promising Areas of Study Oncology Times · 2003
    3. Development of a new gas chromatography–mass spectrometry (GC–MS) methodology for the evaluation of 5α-reductase activity Talanta · 2013 · 17 citations
    4. Design, synthesis and structure-activity relationships studies on steroidal aromatase and 5α-reductase inhibitors as anti-tumors Estudo Geral (Universidade de Coimbra) · 2013
    5. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review Therapeutics and Clinical Risk Management · 2009 · 33 citations
    6. Structural perspectives on the androgen receptor, the elusive shape-shifter Steroids · 2024
    7. 5α‐Reductase Inhibitors 2014
    8. Men??s Health Drugs in R & D · 1999
    9. Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways International Journal of Molecular Sciences · 2023 · 54 citations
    10. Wnt signaling: the good and the bad Acta Biochimica et Biophysica Sinica · 2008 · 48 citations
    11. Dutasteride Drugs · 2008 · 45 citations
    12. Finasteride Drugs · 1999 · 40 citations
    13. Pharmacological Profile of 9,11-Dehydrocortexolone 17α-Butyrate (CB-03-04), a New Androgen Antagonist with Antigonadotropic Activity Arzneimittelforschung · 2011 · 1 citations
    14. WNT10B (wingless-type MMTV integration site family) Atlas of genetics and cytogenetics in oncology and haematology · 2018
    15. Synthesis, Anticancer and Molecular Docking Studies of 2-(4-chlorophenyl)-5-aryl-1,3,4-Oxadiazole Analogues Medicinal chemistry · 2013 · 8 citations
    16. An update on the use of 5alpha-reductase inhibitors Drugs of today · 2004 · 7 citations
    17. Risks and side effects in the medical management of benign prostatic hyperplasia Prostate International · 2023 · 26 citations
    18. Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy Journal of Clinical Oncology · 2007 · 1 citations
    19. 5-alpha reductase inhibitors use in prostatic disease and beyond Translational Andrology and Urology · 2023
    20. Isotopic Abundance Ratio Analysis of the Consciousness Energy Healing Treated Flutamide using LC-MS and GC-MS Spectrometry Open Access Journal of Cancer & Oncology · 2021 · 1 citations
    21. Interactions between Lower Urinary Tract Symptoms and Cardiovascular Risk Factors Determine Distinct Patterns of Erectile Dysfunction: A Latent Class Analysis The Journal of Urology · 2013 · 12 citations
    22. <i>Retraction of:</i> Bansal and Arora. J Endourol. Epub ahead of print; DOI: 10.1089/end.2016.0696 Journal of endourology · 2017
    23. French administrative health care database (SNDS): The value of its enrichment Thérapie · 2018 · 64 citations
    24. Circulating androgen regulation by androgen-catabolizing gut bacteria in male mouse gut Gut Microbes · 2023 · 37 citations
    25. Finasteride Inhibits Melanogenesis throughthe Regulation of Melanocortin 1 Receptorin Melanocytes 한국생물공학회 학술대회 · 2015
    26. Life Sciences Discovery and Technology Highlights SLAS TECHNOLOGY · 2019
    27. Screening: seeking a balance Lancet Oncology · 2006
    28. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review Expert opinion on therapeutic patents · 2017 · 70 citations
    29. The enzyme and inhibitors of 4-ene-3-oxosteroid 5α-oxidoreductase Steroids · 1995 · 64 citations
    30. Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction Circulation · 2015 · 56 citations